Alector Inc Cash Flow Conversion Efficiency
Alector Inc cash flow conversion efficiency. Based on the latest financial reports, Alector Inc (ALEC) has a cash flow conversion efficiency ratio of -1.360x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.69 Million) by net assets ($30.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alector Inc (2016–2025)
Cash flow conversion efficiency of Alector Inc from 2016 to 2025. This chart illustrates how Alector Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alector Inc share price for real-time trading data and today's change.
Alector Inc Cash Flow Conversion Ratio Explained
Alector Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alector Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alector Inc ranked by their cash flow conversion efficiency. Also see Alector Inc (ALEC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Walrus New Material Co Ltd
SHE:003011
|
0.004x |
|
Healius Ltd
AU:HLS
|
0.162x |
|
Rossari Biotech Limited
NSE:ROSSARI
|
0.024x |
|
AMC Networks Inc
NASDAQ:AMCX
|
0.060x |
|
Lionheart Holdings
NASDAQ:CUB
|
0.000x |
|
Velos Acquisition I Corp.
NASDAQ:VLOS
|
-0.003x |
|
Zhejiang Heda Technology Co Ltd
SHG:688296
|
-0.012x |
|
XiAn Tourism Co Ltd
SHE:000610
|
0.011x |
Annual Cash Flow Conversion Efficiency for Alector Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alector Inc from 2016 to 2025. Review Alector Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.65 Million | $-184.03 Million | -6.004x | -231.17% |
| 2024-12-31 | $126.80 Million | $-229.91 Million | -1.813x | -32.08% |
| 2023-12-31 | $134.16 Million | $-184.16 Million | -1.373x | -1348.03% |
| 2022-12-31 | $214.44 Million | $-20.33 Million | -0.095x | -109.55% |
| 2021-12-31 | $300.72 Million | $298.55 Million | 0.993x | +259.29% |
| 2020-12-31 | $267.53 Million | $-166.73 Million | -0.623x | -22.22% |
| 2019-12-31 | $194.74 Million | $-99.31 Million | -0.510x | +61.03% |
| 2018-12-31 | $-97.40 Million | $127.46 Million | -1.309x | -483.18% |
| 2017-12-31 | $-52.03 Million | $-17.77 Million | 0.342x | -34.53% |
| 2016-12-31 | $-24.91 Million | $-12.99 Million | 0.522x | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more